Matthew A. Dean
Plus aucun poste en cours
Profil
Matthew A.
Dean is Vice President of Finance and Administration for Arriva Pharmaceuticals, Inc. Prior to joining Arriva, he was Vice President of Finance, Systems and Administration for Silicon Energy Corp.
Previously, Mr. Dean held senior finance positions at Cotelligent Group, Inc. and USL Capital Corp.
He has over 15 years experience in accounting, finance and senior management.
Mr. Dean received a BA degree in Economics and Accounting from Claremont McKenna College.
He is a California Certified Public Accountant.
Anciens postes connus de Matthew A. Dean
| Sociétés | Poste | Fin |
|---|---|---|
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Directeur Administratif | 19/01/2011 |
USL Capital Corp.
 USL Capital Corp. Investment ManagersFinance Part of Ford Motor Co., USL Capital Corp. manages portfolios of commercial leases. The company is based in San Francisco, CA. | Corporate Officer/Principal | - |
| Cotelligent Group, Inc. | Corporate Officer/Principal | - |
| Silicon Energy Corp. | Directeur Financier/CFO | - |
Formation de Matthew A. Dean
| Claremont McKenna College | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
| Silicon Energy Corp. | Technology Services |
| Cotelligent Group, Inc. | |
USL Capital Corp.
USL Capital Corp. Investment ManagersFinance Part of Ford Motor Co., USL Capital Corp. manages portfolios of commercial leases. The company is based in San Francisco, CA. | Finance |
